What we are seeing in the market.
Operator analysis of health markets in Europe, the US, and MENA: four monthly Vital Signs editions, the PROGNOSIS flagship, perspectives, and the reference work behind them.
Operator analysis of health markets in Europe, the US, and MENA: four monthly Vital Signs editions, the PROGNOSIS flagship, perspectives, and the reference work behind them.
Vital Signs · MedTech
A device can wait about two years between its first approval and its second, and the lead piece sets out what stretched the longest waits. This month's deals show what buyers paid for medtech companies, from $240 million to $2.1 billion, and what Stryker's $400 million in CMR Surgical buys it.
27 October 2026
Perspective · AI Drug DiscoveryThree AI drug discovery companies at the HealthVC Summit each named a different missing experiment. What AI has already changed in drug R&D, what it has not, and where the capital is going.
News · Venture BuildingHealthSeed and Mangold Consultants are introducing Venitara: AI regulatory tools with senior expert review for medical device, SaMD, and IVD companies.
News · Venture BuildingHealthSeed and MIA Solutions are bringing ZINOS to hospital research units: one clinical trial system, inside the institution, under its own control.
Perspective · EcosystemHealthSeed AG joins Telehealth Connect 2026 in Tunis as a strategic partner. Why the region's growth story will be settled where products meet health systems.